Item 5.02. Departure of Directors or Certain Officers; Election of Directors;


           Appointment of Certain Officers; Compensatory Arrangement of Certain
           Officers.

On January 17, 2022, upon the recommendation of the Nominating and Corporate Governance Committee of the Board of Directors (the "Board") of Kymera Therapeutics, Inc. (the "Company"), the Board appointed John Maraganore, Ph.D. to join the Board, effective as of January 17, 2022. Dr. Maraganore will serve as a Class III director until his term expires at the 2023 annual meeting of stockholders at which time he will stand for election by the Company's stockholders. The Board determined that Dr. Maraganore is independent under the listing standards of Nasdaq. The compositions of the Audit Committee, the Compensation Committee and the Nominating and Corporate Governance Committee remain unchanged.

As a non-employee director, Dr. Maraganore will receive cash compensation and an equity award for his Board service in accordance with the Company's Non-Employee Director Compensation Policy, as amended. Dr. Maraganore is not a party to any transaction with the Company that would require disclosure under Item 404(a) of Regulation S-K, and there are no arrangements or understandings between Dr. Maraganore and any other persons pursuant to which he was selected as a director. In addition, Dr. Maraganore has entered into an indemnification agreement with the Company consistent with the form of indemnification agreement entered into between the Company and its existing non-employee directors.

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses